Prestige Consumer Healthcare (PBH) Cash & Current Investments (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Cash & Current Investments came in at $62.4 million in Q4 2025, up 22.6% year-on-year from $50.9 million in Q4 2024, and down 47.63% quarter-over-quarter from $119.1 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Cash & Current Investments (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Cash & Current Investments history runs 16 years deep, the most recent figure standing at $62.4 million for Q4 2025.
- On a quarterly basis, Cash & Current Investments rose 22.6% year-over-year to $62.4 million in Q4 2025; TTM through Dec 2025 was $62.4 million, a 22.6% increase from a year earlier, with the FY2025 full-year figure at $97.9 million, up 110.64% from the prior year.
- Cash & Current Investments declined to $62.4 million in Q4 2025 per PBH's latest filing, from $119.1 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $163.6 million in Q2 2021 and bottomed at $21.0 million in Q4 2021.
- The 5-year median for Cash & Current Investments is $53.1 million (2023), against an average of $64.5 million.
- Biggest YoY gain for Cash & Current Investments was 310.88% in 2022; the steepest drop was 78.08% in 2022.
- Year by year, Cash & Current Investments stood at $21.0 million in 2021, then surged by 310.88% to $86.4 million in 2022, then declined by 26.34% to $63.6 million in 2023, then fell by 20.03% to $50.9 million in 2024, then advanced by 22.6% to $62.4 million in 2025.
- Per Business Quant, the three latest PBH Cash & Current Investments figures stand at $62.4 million (Q4 2025), $119.1 million (Q3 2025), and $139.5 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.41 Bn | 2.35 Bn | 157.37 Mn | 62.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62.37 Mn |
| Sep 30, 2025 | 119.11 Mn |
| Jun 30, 2025 | 139.50 Mn |
| Mar 31, 2025 | 97.88 Mn |
| Dec 31, 2024 | 50.87 Mn |
| Sep 30, 2024 | 51.54 Mn |
| Jun 30, 2024 | 34.26 Mn |
| Mar 31, 2024 | 46.47 Mn |
| Dec 31, 2023 | 63.62 Mn |
| Sep 30, 2023 | 60.07 Mn |
| Jun 30, 2023 | 54.58 Mn |
| Mar 31, 2023 | 58.49 Mn |
| Dec 31, 2022 | 86.36 Mn |
| Sep 30, 2022 | 42.44 Mn |
| Jun 30, 2022 | 35.87 Mn |
| Mar 31, 2022 | 27.19 Mn |
| Dec 31, 2021 | 21.02 Mn |
| Sep 30, 2021 | 42.82 Mn |
| Jun 30, 2021 | 163.62 Mn |
| Mar 31, 2021 | 32.30 Mn |